CLRN1 — clarin 1

The CLRN1 gene provides instructions for making a protein called clarin-1, which is essential for the normal function of both the inner ear and the retina (the light-sensitive tissue at the back of the eye). In the inner ear, clarin-1 helps maintain the tiny hair-like structures that detect sound. In the retina, it is found in support cells called Müller glia, which help keep the light-detecting cells (photoreceptors) healthy. When the CLRN1 gene is mutated, it cannot produce functional clarin-1 protein. This leads to a condition called Usher syndrome type III, which is characterized by a progressive loss of both hearing and vision. The hearing loss usually begins after a child learns to speak and worsens over time. The vision loss is caused by a condition called retinitis pigmentosa, which starts with night blindness and gradually narrows the field of vision until central vision is also lost. In some cases, mutations in this gene can cause vision loss alone, without affecting hearing. CLRN1-related conditions are inherited in an autosomal recessive pattern. This means that a person must inherit two mutated copies of the gene (one from each parent) to develop the disease. Parents who carry only one mutated copy are called carriers; they typically do not show any symptoms but have a 25% chance of passing the condition to their children with each pregnancy. Genetic testing can confirm the diagnosis and help families understand their risks.

Gene description: CLRN1 encodes clarin-1, a transmembrane protein localized to stereocilia of hair cells and photoreceptor inner segments.

Patient and family guide: The CLRN1 gene provides instructions for making a protein called clarin-1, which is essential for the normal function of both the inner ear and the retina (the light-sensitive tissue at the back of the eye). In the inner ear, clarin-1 helps maintain the tiny hair-like structures that detect sound. In the retina, it is found in support cells called Müller glia, which help keep the light-detecting cells (photoreceptors) healthy. When the CLRN1 gene is mutated, it cannot produce functional clarin-1 protein. This leads to a condition called Usher syndrome type III, which is characterized by a progressive loss of both hearing and vision. The hearing loss usually begins after a child learns to speak and worsens over time. The vision loss is caused by a condition called retinitis pigmentosa, which starts with night blindness and gradually narrows the field of vision until central vision is also lost. In some cases, mutations in this gene can cause vision loss alone, without affecting hearing. CLRN1-related conditions are inherited in an autosomal recessive pattern. This means that a person must inherit two mutated copies of the gene (one from each parent) to develop the disease. Parents who carry only one mutated copy are called carriers; they typically do not show any symptoms but have a 25% chance of passing the condition to their children with each pregnancy. Genetic testing can confirm the diagnosis and help families understand their risks.

Gene function: CLRN1 is expressed in the retina, particularly in the photoreceptor inner segments. It is believed to play a role in maintaining the structural integrity and function of photoreceptor cells, potentially by influencing membrane organization or protein trafficking. Mutations in CLRN1 lead to Usher syndrome type IIIA, characterized by progressive vision loss alongside hearing impairment.

Protein structure: The CLRN1 gene encodes clarin-1, a protein that is predicted to contain 232 amino acids in its main isoform. Clarin-1 is an integral membrane glycoprotein belonging to the tetraspanin family. Its structure includes a cytosolic N-terminus, four helical transmembrane domains, two extracellular loops, and a cytosolic C-terminus. The protein features a single glycosylation consensus site located in the first extracellular loop between the first and second transmembrane domains. The C-terminus of clarin-1 contains an endoplasmic reticulum membrane retention signal (TKGH). Clarin-1 is thought to assemble into functional complexes at the plasma membrane, where it acts as a molecular scaffold to organize the actin cytoskeleton and recruit other proteins involved in cell adhesion and signaling. Multiple alternative splice variants of the CLRN1 gene exist, potentially encoding proteins of varying lengths and transmembrane segment numbers, though the 232-amino acid isoform is the most extensively studied.

Molecular function: The CLRN1 gene encodes clarin-1, a four-transmembrane domain protein belonging to the tetraspanin family. Clarin-1 is thought to function as a molecular scaffold, recruiting proteins involved in cell adhesion to distinct plasma membrane regions and playing a role in organizing the actin cytoskeleton. In the inner ear, clarin-1 is essential for the morphogenesis and maintenance of hair bundle stereocilia, which are actin-rich structures required for mechanotransduction. In the retina, the molecular function of clarin-1 is less well understood but is believed to be critical for the structural integrity and function of Müller glia cells. Given its localization to Müller glia, clarin-1 may be involved in regulating the architecture of these cells and their interactions with photoreceptors. The loss of clarin-1 function in Müller glia likely disrupts the supportive environment required for photoreceptor survival, leading to the progressive retinal degeneration observed in Usher syndrome type III.

Expression pattern: The CLRN1 gene is expressed in the neurosensory epithelia of the inner ear and the retina. In the inner ear, expression is specific to the inner and outer hair cells of the organ of Corti and the spiral ganglion cells, where it is essential for the development and maintenance of stereocilia. In the retina, the cellular distribution of CLRN1 has been a subject of investigation. Recent studies using highly sensitive RNAscope in situ hybridization and single-cell RNA sequencing have demonstrated that Clrn1 transcripts in both mouse and human adult retinas are concentrated in the inner nuclear layer (INL) and are specifically expressed in Müller glia cells, rather than in photoreceptors. This localization suggests that Müller glia play a central role in the retinal pathology of Usher syndrome type III.

Mutation spectrum: The mutation spectrum of the CLRN1 gene includes missense, nonsense, frameshift, and splice-site mutations, as well as small deletions and insertions. Over 20 pathogenic variants have been identified. The mutations are distributed across the gene, affecting the cytosolic N-terminus, the transmembrane domains, and the extracellular loops of the clarin-1 protein. A notable feature of the CLRN1 mutation spectrum is the presence of founder mutations in specific populations. The p.Tyr176Ter (Fin major) mutation is highly prevalent in the Finnish population, while the p.Asn48Lys (N48K) mutation is a common founder mutation among Ashkenazi Jews. These founder effects significantly influence the prevalence of Usher syndrome type IIIA in these groups.

Pathogenic variants: 1. p.Asn48Lys (c.144T>G) - A common founder mutation in the Ashkenazi Jewish population, associated with Usher syndrome type IIIA. It exhibits variable phenotypic severity. 2. p.Tyr176Ter (c.528T>G) - Known as the Fin(major) mutation, this nonsense variant is the most frequent cause of Usher syndrome type IIIA in the Finnish population. 3. p.Met120Lys (c.359T>A) - Known as the Fin(minor) mutation, this missense variant is also found in the Finnish population and causes Usher syndrome type IIIA. 4. p.Ala123Asp (c.368C>A) - A missense mutation associated with nonsyndromic retinitis pigmentosa (RP61), suggesting a hypomorphic effect. 5. c.459_461delATT - A 3-base pair deletion resulting in the loss of an amino acid, identified in patients with Usher syndrome type IIIA.

Clinical significance: Mutations in the CLRN1 gene primarily cause Usher syndrome type IIIA (USH3A), an autosomal recessive disorder characterized by postlingual, progressive sensorineural hearing loss, variable vestibular dysfunction, and the onset of retinitis pigmentosa (RP) symptoms. The retinal phenotype typically begins with nyctalopia (night blindness) and progresses to constriction of the visual fields and loss of central visual acuity, usually by the second decade of life. The retinal degeneration in USH3A is a severe photoreceptor dystrophy with distinctive features, including a whitish granular posterior pole appearance and cystic maculopathy. In addition to USH3A, mutations in CLRN1 can also cause a form of nonsyndromic autosomal recessive retinitis pigmentosa (RP61). Patients with RP61 experience progressive vision loss without the accompanying hearing or vestibular deficits seen in Usher syndrome. The severity and age of onset of both the auditory and ocular phenotypes can vary widely, even among individuals with the same mutation, suggesting the influence of genetic modifiers or environmental factors.

Inheritance: Autosomal Recessive

Chromosomal location: 3q25.1

Genotype-phenotype correlations: Genotype-phenotype correlations in CLRN1-associated diseases show significant variability. The most common mutation, p.Asn48Lys (N48K), is associated with Usher syndrome type IIIA and exhibits a wide range of phenotypic severity, with the age of onset for hearing loss varying from infancy to over 35 years. Some missense mutations, particularly those occurring in the transmembrane domains (e.g., p.Ala123Asp), have been identified in patients with nonsyndromic retinitis pigmentosa (RP61). These are hypothesized to be hypomorphic mutations that retain enough function to preserve hearing but are insufficient to prevent retinal degeneration. The presence of null mutations, such as nonsense mutations or large deletions, typically results in the more severe syndromic phenotype of USH3A. However, phenotypic heterogeneity is observed even among siblings with the same genotype, indicating that other genetic or environmental factors modulate the disease expression.

Research and therapeutic approaches: Current therapeutic approaches for CLRN1-associated diseases are primarily supportive, focusing on managing symptoms through hearing aids, cochlear implants, and visual aids. However, several investigational strategies are in the pipeline. Gene therapy is a major area of focus, aiming to deliver a functional copy of the CLRN1 gene to the affected cells in the retina and inner ear using adeno-associated virus (AAV) vectors. Preclinical studies in animal models have shown promise in preserving hair cell function and retinal integrity. Clinical trials for retinal gene therapy are actively being explored. For example, the Uni-Rare study is evaluating patients with inherited retinal diseases, including those with CLRN1 mutations, to build a natural history database that will support future interventional trials. While there are currently no FDA-approved gene therapies specifically for CLRN1 (unlike Luxturna for RPE65), the identification of Müller glia as the primary site of CLRN1 expression in the retina provides a specific cellular target for these emerging therapies. Other potential approaches, such as antisense oligonucleotides or small molecules, are also being investigated to address specific mutation types.

Diagnostic testing: Diagnostic testing for CLRN1 mutations typically involves targeted gene panels for Usher syndrome or inherited retinal diseases, which can identify sequence variants and small deletions/insertions. Whole exome sequencing (WES) or whole genome sequencing (WGS) may also be employed, particularly when panel testing is inconclusive or when a broader genetic evaluation is needed. Genetic counseling is strongly recommended for individuals and families undergoing testing for CLRN1 mutations. Counseling helps patients understand the autosomal recessive inheritance pattern, the implications of positive results for their prognosis, and the risks to family members. It also provides guidance on family planning and the potential availability of clinical trials or emerging therapies.

Animal models: Key animal models for CLRN1 include mouse and zebrafish. The Clrn1 knockout (Clrn1 -/-) mouse model exhibits early-onset hearing loss that rapidly progresses to severe levels, with disorganization of outer hair cell stereocilia and subsequent hair cell loss, mimicking the auditory phenotype of Usher syndrome type III. However, like many mouse models of Usher syndrome, it lacks a retinal degeneration phenotype, likely due to interspecies differences in photoreceptor ultrastructure and the absence of well-defined calyceal processes in mice. To better model the retinal phenotype, a clrn1 mutant zebrafish model was developed using CRISPR-Cas9. The clrn1 -/- zebrafish show progressive disruption of the cone photoreceptor mosaic and age-dependent cone photoreceptor changes, providing a valuable model for studying the mechanisms of retinal degeneration associated with USH3A. These models have revealed that CLRN1 is essential for the formation and maintenance of properly shaped hair bundles in the inner ear and plays a crucial role in maintaining the integrity of photoreceptor organization in the retina.

Population genetics: The population genetics of CLRN1 are strongly influenced by founder effects in specific genetically isolated populations. In the Finnish population, the p.Tyr176Ter (Fin major) mutation is highly prevalent, making Usher syndrome type III the most common form of Usher syndrome in Finland (accounting for about 40% of cases). In the Ashkenazi Jewish population, the p.Asn48Lys (N48K) mutation is a common founder variant, with a carrier frequency estimated at 0.7% in the New York area. Outside of these specific populations, Usher syndrome type III is very rare, representing only a small fraction of all Usher syndrome cases globally.

Selected references: 1. Adato A, et al. USH3A transcripts encode clarin-1, a four-transmembrane-domain protein with a possible role in sensory synapses. Eur J Hum Genet, 2002. PMID: 12080385 2. Joensuu T, et al. Mutations in a novel gene with transmembrane domains underlie Usher syndrome type 3. Am J Hum Genet, 2001. PMID: 11438997 3. Fields RR, et al. Usher syndrome type III: revised genomic structure of the USH3 gene and identification of novel mutations. Am J Hum Genet, 2002. PMID: 12145752 4. Geng R, et al. Usher syndrome IIIA gene clarin-1 is essential for hair cell function and associated neural activation. Hum Mol Genet, 2009. PMID: 19414487 5. Xu L, et al. Clarin-1 expression in adult mouse and human retina highlights a role of Müller glia in Usher syndrome. J Pathol, 2020. PMID: 32185805 6. Nonarath HJT, et al. The USH3A causative gene clarin1 functions in Müller glia to maintain photoreceptor survival. PLoS Genet, 2025. PMID: 38446789 7. Smirnov VM, et al. Retinal Phenotype of Patients with CLRN1-Associated Usher 3A Syndrome. Invest Ophthalmol Vis Sci, 2022. PMID: 35389456